Rapport Therapeutics Inc (RAPP) - News Archive

On September 9, 2025, Rapport Therapeutics, Inc., a burgeoning clinical-stage biotechnology firm focused on developing small molecule precision medicines for neurological and psychiatric disorders, announced a significa...

Recent developments in the clinical evaluation of RAP-219, an investigational treatment targeting focal onset seizures and central nervous system (CNS) disorders, have shown significant promise. Rapport Therapeutics has...

In a recent Investor and Analyst Day, Rapport Therapeutics made noteworthy strides in its ongoing commitment to advancing treatments for neurological disorders, particularly refractory focal epilepsy. The company announ...

Title : Rapport Therapeutics: Promising Advances in Seizure Management Amid Financial Challenges:Rapport Therapeutics Inc has recently made significant strides in the realm of pharmaceutical development, particularly re...

Rapport Therapeutics recently announced plans to present data at the American Epilepsy Society Annual Meeting, focusing on the outcomes of their Phase 2a trial, as well as preclinical and Phase 1 clinical data associate...

In the realm of pain management and therapeutic innovation, Rapport Therapeutics is poised to make significant waves as it prepares to present compelling preclinical data on its TARP8 (TARPs and AMPA Receptor Modulation...

: This article aims to provide a factual account of Rapport Therapeutics recent closure of its initial public offering (IPO) and its commitment to developing innovative small molecule medicines for central nervous syste...